Best Forestry Stocks To Invest In Right Now

Philadelphia-based CDI Corp. (NYSE: CDI  ) has won a $36 million contract to provide watercraft engineering and marine services to the U.S. Navy.

On Monday, the engineering firm announced it has been awarded a new SEAPORT task order from the Naval Surface Warfare Center's Combatant Craft Division (CCD). The task order has a maximum duration of two years, and calls for CDI to provide plans, designs, and prototypes for installations and alterations aboard "all types of combatant craft, boats, watercraft and associated systems" supported by the CCD.

CDI said it has been performing this kind of work for the Navy for nine years. CDI Global Engineering and Technology Solutions President Robert Giorgio was quoted as saying: "We have a track record of success with previous national defense and homeland security initiatives and we look forward to continuing to provide the kind of engineering support and services that such important projects require and deserve."

link

Best Forestry Stocks To Invest In Right Now: Coherent Inc.(COHR)

Coherent, Inc. provides photonics-based solutions for a range of commercial and scientific research applications worldwide. The company engages in designing, manufacturing, servicing, and marketing lasers, laser tools, precision optics, and related accessories. Its products are used in a range of applications, including microelectronics, scientific research and government programs, original equipment manufacturer components and instrumentation, and materials processing markets. The company markets its products primarily through a direct sales force, as well as through independent representatives. Coherent, Inc. was founded in 1966 and is headquartered in Santa Clara, California.

Advisors' Opinion:

• [By Brian Stoffel]

  For decades, the standard technology in the laser industry has been the carbon-based laser. In reality, these lasers are still commonly used, and sold in bulk by the likes of Rofin-Sinar (NASDAQ: RSTI  ) and Coherent (NASDAQ: COHR  ) . They are used largely for precision cutting of large pieces of metal.

• [By Brian Stoffel]

  Rofin-Sinar (NASDAQ: RSTI  ) , Coherent (NASDAQ: COHR  ) , Newport (NASDAQ: NEWP  ) , and JDS Uniphase (NASDAQ: JDSU  ) all offer fiber-optic lasers as well.

• [By Evan Niu, CFA]

  What: Shares of Coherent (NASDAQ: COHR  ) ran higher by as much as 16% after the company reported fiscal second-quarter earnings.

  So what: Revenue in the quarter added up to $200.1 million, with adjusted earnings per share of $0.84. Both headline figures were ahead of consensus forecasts, which were perched at $198.2 million in sales and an adjusted profit of $0.80 per share. CEO John Ambroseo said demand in Coherent's commercial end markets improved, resulting in record bookings for materials processing.

Best Forestry Stocks To Invest In Right Now: Clayton Williams Energy Inc (CWEI)

Clayton Williams Energy, Inc. (CWEI), incorporated on December 27, 1991, is an independent oil and gas company engaged in the exploration for and production of oil and natural gas primarily in Texas, Louisiana and New Mexico. The Company operates in two segments: oil and gas exploration and production and contract drilling services. As of December 31, 2012, its portfolio of oil and natural gas reserves is weighted in favor of oil, with approximately 77% of its proved reserves consisting of oil and natural gas liquids (NGLs) and approximately 23% consisting of natural gas. During the year ended December 31, 2012, the Company added proved reserves of 20,443 million barrels of oil equivalent (MBOE) through extensions and discoveries, had downward revisions of 6,615 MBOE and had purchases of minerals-in-place of 3,504 MBOE and had a sales of minerals-in-place of 725 MBOE. As of December 31, 2012, CWEI held interests in 3,031 gross (1749 net) producing oil and gas wells and owned leasehold interests in approximately 951,000 gross (471,000 net) undeveloped acres. On March 14, 2012, its wholly owned subsidiary, Southwest Royalties, Inc. (SWR), completed the mergers of each of the 24 limited partnerships, of which SWR is the general partner (SWR Partnerships) into SWR.

Permian Basin

The Company�� Permian Basin is a sedimentary basin in West Texas and Southeastern New Mexico. The Permian Basin covers an area approximately 250 miles wide and 350 miles long and contains commercial accumulations of oil and gas in multiple stratigraphic horizons at depths ranging from 1,000 feet to over 25,000 feet. During 2012, the Company drilled and completed 87 gross (80.2 net) operated wells in the Permian Basin and conducted various remedial operations on other wells. As of December 31, 2012, the Company had two rigs in this area.

Giddings Area

The Company�� Austin Chalk formation is an upper Cretaceous geologic formation in the Gulf Coast region of the United States th! at stretches across numerous fields in Texas and Louisiana. The Austin Chalk formation is generally encountered at depths of 5,500 to 7,000 feet. Horizontal drilling is the primary technique used in the Austin Chalk formation. Its wells in this area were drilled as horizontal wells, many with multiple laterals in different producing horizons, including the Austin Chalk, Buda and Georgetown formations in East Central Texas. The Eagle Ford Shale formation lies immediately beneath the Austin Chalk formation where the Company have approximately 177,000 net acres in production. As of December 31, 2012, the Company is using one of its drilling rigs in the Giddings Area to drill horizontal wells in the Eagle Ford Shale formation.

South Louisiana

During 2012, the Company drilled and completed the Hassinger ETAL #1, an exploratory well in Jefferson Parish, Louisiana. The Company plan to commence drilling operations on the Macon Stringer Heirs #1, an exploratory well in Terrebonne Parish in 2013.

Natural Gas Services

The Company owns an interest in and operates natural gas service facilities in the states of Texas and Louisiana. These natural gas service facilities consist of interests in approximately 314 miles of pipeline, three treating plants, one dehydration facility, and seven wellhead type treating and/or compression stations. Its operated gas gathering and treating activities exist to facilitate the transportation and marketing of its operated oil and gas production.

Advisors' Opinion:

• [By Seth Jayson]

  Clayton Williams Energy (Nasdaq: CWEI  ) is expected to report Q1 earnings around April 24. Here's what Wall Street wants to see:

  The 10-second takeaway
  Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Clayton Williams Energy's revenues will decrease -8.9% and EPS will shrink -32.8%.

Top 5 Medical Companies To Watch In Right Now: AcelRx Pharmaceuticals Inc.(ACRX)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain in the United States. The company develops ARX-01, a Sufentanil NanoTab PCA system, which completed Phase II clinical trial for acute post-operative pain. The Sufentanil NanoTab PCA system consists of sufentanil, a high therapeutic index opioid; NanoTabs, a non-invasive sublingual dosage form; and a handheld PCA device that enables simple patient-controlled delivery of NanoTabs in the hospital setting and eliminates the risk of programming errors. Its products also include ARX-02, a Sufentanil NanoTab BTP Management System that completed Phase II clinical trial for the treatment of cancer breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which completed Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a ph ysician?s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood, California.

Advisors' Opinion:

• [By Roberto Pedone]

  One stock that's starting to trend within range of triggering a major breakout trade is AcelRx Pharmaceuticals (ACRX), a specialty pharmaceutical company involved in the development and commercialization of therapies for the treatment of acute and breakthrough pain. This stock is off to a booming start for the bulls so far in 2013, with shares up a whopping 189%.

  If you take a look at the chart for AcelRx Pharmaceuticals, you'll notice that this stock recently formed a double-bottom chart pattern at $11.46 to $11.43 a share. Following that bottom, shares of ACRX have now started to spike higher and move within range of taking out some key near-term overhead resistance levels. If those levels get taken out with volume soon, then ACRX will trigger a major breakout trade.

  Traders should now look for long-biased trades in ACRX if it manages to break out above some near-term overhead resistance levels at $12.57 to its 52-week high at $13.50 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average volume of 648,667 shares. If that breakout triggers soon, then ACRX will set up to enter new 52-week-high territory above $13.50, which is bullish technical price action. Some possible upside targets off that breakout are $17 to $20 a share.

  Traders can look to buy ACRX off any weakness to anticipate that breakout and simply use a stop that sits right below $11.43 a share, or near its 50-day at $10.27 a share. One could also buy ACRX off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.

  This stock is a favorite target of the bears, since the current short interest as a percentage of the float for ACRX is very high at 16.9%. The bears have also been increasing their bets from the last reporting period by 35.5%, or by about 836,000 shares. If that breakout triggers soon

• [By Eric Volkman]

  AcelRx (NASDAQ: ACRX  ) has slapped a price tag on its recently announced common stock offering. The company's shares will be sold to the market in an underwritten public flotation at a cost of $11.65 apiece. The firm has also granted its underwriters a 30-day purchase option for up to an additional 570,000 shares.

• [By StockMatusow]

  One company that had an offering received very well is AcelRx Pharmaceuticals (ACRX). AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain. On July 19, 2013, AcelRx offered 570,000 shares priced at $11.65. Investors aggressively bought the offering and the stock now sits at $11.96 per share. We covered AcelRx this year when it was about $6.50 per share. It reached highs since of $13.50, which effectively makes it more than a double.

Best Forestry Stocks To Invest In Right Now: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

Companion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Shares of Myriad Genetics (NASDAQ: MYGN) got a boost, shooting up 10.63 percent to $30.07 after the company reported upbeat fiscal second-quarter results and lifted its revenue outlook for the year. Myriad also bought Crescendo Bioscience for $270 million.

• [By Ben Levisohn]

  Shares of Myriad Genetics (MYGN) have plunged this morning after a U.S. agency said it would pay less for its breast-cancer tests.

  The Wall Street Journal has the details:

  The price of a popular genetic test that predicts women’s risk of breast cancer is likely to drop in the New Year after the agency that administers Medicare benefits said it would slash its reimbursement rate for the test by half.

  The rate cut goes into effect on Jan. 1, 2014, with consequences for genetic-testing companies, particularly�Myriad Genetics�Inc., the dominant supplier of screenings for mutations in the genes known as BRCA1 and BRCA2. Medicare will pay a maximum of $1,440 for the BRCA test, a 48.5% decline from the rate of $2,795 it paid in 2013, according to a notice published Friday afternoon on the website of the Centers for Medicare and Medicaid Services.

  The announcement comes just months after the Supreme Court said that Myriad couldn’t patent the BRCA genes and allowed companies like Quest Diagnostics (DGX) to offer its own tests, the Wall Street Journal says.

  JPMorgan’s Tycho Peterson and team call the decisions a “significant negative” for Myriad Genetics:

  We view this confirmation of the rate cut as a significant negative for MYGN as the company will have a difficult time explaining why CMS believes the BRCA test should cost less than half of MYGN�� list price ($4,040).

  Primary question is how quickly this will impact private payors. With increased competition coming to the market at significantly lower prices than MYGN, we expect payors will begin to influence physicians to use competitive tests, while leaving open the option for patients to use MYGN�� test if they want to pay the additional cost (+$1,500) out of pocket. In our prior physician survey (found here), all 25 physicians surveyed were willing to convert away from MYGN for a competitive product and 76% viewed price as a ��/li>

Best Forestry Stocks To Invest In Right Now: Saia Inc.(SAIA)

Saia, Inc., an asset-based trucking company, provides transportation and supply chain solutions primarily to the retail, chemical, and manufacturing industries in the United States. The company, through it subsidiary, Saia Motor Freight Line, LLC, offers regional and interregional less than truckload (LTL) services, selected national LTL, and time-definite services. It was formerly known as SCS Transportation, Inc. Saia, Inc. was founded in 2000 and is headquartered in Johns Creek, Georgia.

Advisors' Opinion:

• [By Ben Levisohn]

  Wunderlich’s Nicholas Bender thinks FedEx’s results bode well for Old Dominion (ODFL), Con-way (CNW) and Saia (SAIA):

  We expect all less-than-truckload carriers to benefit in 2Q14 from the same trends that carried FedEx Freight to a banner 4Q14. This includes Hold-rated Old Dominion, which will continue to grow at well above market rates, and Buy-rated Con-way, which we believe can leverage a strong 2Q14 to prime the pump on margin enhancement efforts. Our favorite name in the space remains Saia (SAIA-$42.92, Buy), which will once again see accelerating tonnage growth in 2Q14. Though tonnage growth will moderate in� 2H14 due to steeper comps, there remains considerable potential for the company to boost yield and continue winning incremental business with new accounts.

• [By John Udovich]

  Despite what can best be described as a�soft economy, small cap trucking stocks YRC Worldwide, Inc (NASDAQ: YRCW), Arkansas Best Corporation (NASDAQ: ABFS), Frozen Food Express Industries, Inc (NASDAQ: FFEX), Saia Inc (NASDAQ: SAIA) and USA Truck, Inc (NASDAQ: USAK) have been trucking some pretty impressive returns since the start of the year. In fact, these small cap trucking stocks are up anywhere from 72% to 150% or so since the start of the year despite the slow economy. Certainly trucking stocks provide a good indicator of how the economy is doing, but might investors be�jumping the gun by pushing up these trucking stocks?